

Supplementary Table 3. Indirect comparisons between anti-diabetes drugs in T1DM patients in terms of HbA1c changes corrected by placebo

Treatment group	Direct comparisons			Indirect comparisons		
	WMD	95% CI	<i>P</i> value	Difference	95% CI	<i>P</i> value
MET vs. placebo	-0.29	-0.50 to -0.08	<0.01			
MET vs. AGI				0.31	-0.29 to 0.90	0.291
vs. TZD				-0.29	-0.74 to 0.15	0.181
vs. GLP-1RA				-0.12	-0.50 to 0.27	0.528
vs. DPP-4i				-0.19	-0.66 to 0.29	0.424
vs. SGLT2i				0.10	-0.19 to 0.39	0.485
vs. Pramlintide				-0.03	-0.47 to 0.40	0.871
AGI vs. placebo	-0.58	-0.82 to -0.33	<0.01			
AGI vs. TZD				-0.60	-1.20 to 0.01	0.051
vs. GLP-1RA				-0.42	-0.85 to 0.001	0.050
vs. DPP-4i				-0.49	-1.08 to 0.10	0.086
vs. SGLT2i				-0.21	-0.55 to 0.13	0.210
vs. Pramlintide				-0.34	-0.87 to 0.19	0.170
TZD vs. placebo	0.05	-0.33 to 0.42	0.81			
TZD vs. GLP-1RA				0.18	-0.09 to 0.44	0.166
vs. DPP-4i				0.11	-0.24 to 0.46	0.485
vs. SGLT2i				0.39	0.16 to 0.63	0.003
vs. Pramlintide				0.26	-0.07 to 0.59	0.109
GLP-1RA vs. placebo	-0.19	-0.29 to -0.1	<0.01			
GLP-1RA vs. DPP-4i				-0.07	-0.24 to 0.10	0.382
vs. SGLT2i				0.22	0.06 to 0.38	0.012
vs. Pramlintide				0.08	-0.11 to 0.28	0.354
DPP-4i vs. placebo	-0.15	-0.34 to 0.04	0.13			
DPP-4i vs. SGLT2i				0.28	0.08 to 0.49	0.010
vs. Pramlintide				0.15	-0.11 to 0.41	0.206
SGLT2i vs. placebo	-0.38	-0.44 to -0.32	<0.01			
SGLT2i vs. pramlintide				-0.13	-0.33 to 0.07	0.174
Pramlintide vs. placebo	-0.26	-0.41 to -0.11	<0.01			

T1DM, type 1 diabetes mellitus; HbA1c, glycosylated hemoglobin; WMD, weighted mean difference; CI, confidence interval; MET, metformin; AGI, alpha glucosidase inhibitor; TZD, thiazolidinedione; GLP-1RA, glucagon-like peptide-1 receptor agonist; DPP-4i, dipeptidyl peptide 4 inhibitor; SGLT-2i, sodium glucose cotransporter 2 inhibitor.